Antihyperglycaemic therapies and cancer risk
Conclusion:
Although the molecular mechanisms are not fully understood, a potential risk of mitogenicity and tumour growth promotion cannot be excluded in case of several antidiabetic drug classes. However, more large-scale, randomized, well-designed clinical studies with especially long follow-up time periods are needed to get reliable answers to these safety issues.
Source: Diabetes and Vascular Disease Research - Category: Endocrinology Authors: Lutz, S. Z., Staiger, H., Fritsche, A., Haring, H.-U. Tags: Invited Reviews Source Type: research
More News: Actos | Bladder Cancer | Cancer | Cancer & Oncology | Diabetes | Endocrinology | Fortamet | Incretin Therapy | Insulin | Lantus | Metformin | Oral Cancer | Pancreas | Pancreatic Cancer | Study | Thyroid | Thyroid Cancer